Bookmark

Add to MyYahoo RSS

Gilead Sciences News

News on Gilead Sciences (Ticker: GILD) continually updated from thousands of sources around the net.

3 hrs ago | Investor's Business Daily

Alexion, 3 Other Top Biotechs Reporting Earnings

The four highest-rated of the market's seven big-cap biotechs are set to report second-quarter earnings this week, each with its own unique storyline.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

8 hrs ago | The Motley Fool

3 Things You Need to Watch on Gilead Sciences Inc. Earnings Call

Here are three things investors should pay attention to during the conference call.

Comment?

Related Topix: Startups, Gilead Sciences, Biotech, Medicine, Healthcare Industry

9 hrs ago | Seeking Alpha

Gilead's Pipeline Requires MacroGenics' ImmunoOncology Platform

Pending data by year-end, we expect GILD to pay above fair value >100% upside for MGNX, reflecting its scarcity value delivering both immuno-oncology exposure and high-throughput drug development.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, MacroGenics, Oncology

12 hrs ago | TheStreet.com

Gilead Expected to Post Sky-High Hep C Sales in June Quarter

Survey: how high do $GILD 's Sovaldi sales need to be tomorrow to move the stock up? - Meg Tirrell July 22, 2014 .

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Business News

16 hrs ago | Daily Press & Argus

Why $1,000 a pill for hepatitis drug?

But it also comes with a scary side effect: a price of $1,000 a pill. Because the pills must be taken once a day for 12 weeks, the cost of treatment comes to $84,000, plus thousands more for other drugs included in the protocol.

Comment?

Related Topix: Hepatitis, Health, Biotech, Healthcare Industry, US News, US Senate, Ron Wyden, Democrat, US Politics, Republican, Chuck Grassley, Cancer

20 hrs ago | BioSpace

Hepatitis C Spurs Unusual Patent Wars Among Big Drug Makers

The intense rivalry to grab a dominating share of the lucrative market for hepatitis C treatments has largely focused on potential pricing and clinical research showing which medicines can cure the largest number of patients in the shortest amount of time.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

Mon Jul 21, 2014

The Motley Fool

Yellen Hates Biotech Stocks! Should You?

Federal Reserve Chairwoman Janet Yellen thinks your small-cap biotech is overvalued.

Comment?

Related Topix: Biotech, Science / Technology, Financial Markets, Medicine, Healthcare Industry, Amgen

Seeking Alpha

Biotechs Have Their 'Irrational Exuberance' Moment: Time To Buy More?

Background : When the Fed noted some froth in "smaller" biotechs last week, large ones also got slammed.

Comment?

Related Topix: Biotech, Biogen Idec, Startups, Medicine, Gilead Sciences, CGI Pharmaceuticals, Healthcare Industry, Financial Markets, Amgen

SFGate

Costly hepatitis C drugs could add $300 to every American's yearly premium, CVS says

Gilead Sciences' new hepatitis C drug receives as much praise for its healing powers as it receives criticism of its price, $84,000 for 12 weeks.

Comment?

Related Topix: Hepatitis, Medicine, Health, Biotech, Healthcare Industry, Retail, CVS, Startups, Gilead Sciences, CGI Pharmaceuticals

CorpWatch

Gilead Sciences Under Investigation for Over-Charging for Hepatitis C Pill

Gilead Sciences of San Francisco is under investigation by the U.S. Senate Finance Committee for charging $84,000 for a 12 week course of a new drug to treat hepatitis C. Gilead sells the exact same course for $900 in poor countries like Egypt and India.

1 comment

Related Topix: Biotech, Medicine, Healthcare Industry, Hepatitis, Health, Startups, Gilead Sciences, Food and Drug Administration, Liver Cancer, US News, Liberal Political News

Barron's

Gilead Sciences: Sovaldi's a Blockbuster, the Question is How Big

We all know Gilead Sciences' hepatitis C treatment, Sovalidi, has been a blockbuster.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Merck , Johnson and Johnson

TheStreet.com

How Will Gilead Sciences (GILD) Stock Be Affected By Solvadi Hepatitis C Finding?

Your browser is not supported. Please upgrade to one of the following browsers: Google Chrome Mozilla Firefox Apple Safari Microsoft Internet Explorer 8+ You may proceed to the site by clicking here , however some pages might not work correctly.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Startups, Gilead Sciences, Mozilla, TheStreet, Financial Markets

Medical News

State highlights: Concerns continue about Coakley-partners antitrust...

The Boston Globe : Judge Grants Coakley's Request For Delay In Partners Antitrust Settlement Criticism of Attorney General Martha Coakley's antitrust pact with the state's largest health care system mounted Thursday as a watchdog panel warned a judge the proposed deal might not meet its goal of holding down medical expenses.

Comment?

Related Topix: Healthcare Law, Law, Biotech, Medicine, Healthcare Industry, Medicaid, Health, Multnomah County, OR

Sun Jul 20, 2014

The Washington Post

Gilead Drug Combination Cures Hepatitis C in HIV Patients

Gilead Sciences Inc.'s Solvadi, controversial because of its price, helps cure hepatitis C in people with HIV, according to researchers who say the drug has the potential to limit a top cause of death in these patients.

Comment?

Related Topix: HIV/AIDS, Health, Hepatitis, Medicine, Biotech, Healthcare Industry, Healthcare Law, Law, Infectious Diseases, Food and Drug Administration

Sat Jul 19, 2014

The Motley Fool

India Just Did What Millions of Americans Wish the U.S. Government Would Do

The United States is unquestionably the premier economic superpower around the globe.

Comment?

Related Topix: Medicine, Biotech, Healthcare Industry

Forbes.com

Friday Sector Leaders: Utilities, Healthcare

The best performing sector as of midday Friday is the Utilities sector, up 1.1%.

Comment?

Related Topix: Pacific Star Communications, Pinnacle West Capital Corporation, Energy, Financial Markets, Biotech, Medicine, Healthcare Industry, Alexion Pharmaceuticals, Taligen Therapeutics

GuruFocus.com

Why AbbVie Looks Like a Sell

Abbvie has put in a level execution so far not long from now, yet the stock has taken off strikingly in the previous two months, picking up 12%.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Healthcare Law, Law

Fri Jul 18, 2014

Investor's Business Daily

Stocks Up In Late Trade; AerCap Nears Resistance

Stocks continued to add to broad gains in late trading Friday and were on pace to end modestly higher on the week.

Comment?

Related Topix: Financial Markets, Biotech, Medicine, Healthcare Industry

Benzinga

Biotech Enters Reporting Season With Large Caps Central To Sector Performance

Biotech stock stocks enter their earnings season with investors increasingly interested in the long-term outlook for product pipelines, although large-cap growth stocks remain central to the sectors performance, an analyst said Friday.

Comment?

Related Topix: Financial Markets, Biotech, Biogen Idec, Hemophilia, Health, Medicine, Healthcare Industry, Startups, Gilead Sciences, Celgene

AmericanBankingNews.com

Gilead Sciences Sees Unusually Large Options Volume

Shares of Gilead Sciences were the target of some unusual options trading activity on Friday.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Stanley

•••
•••
•••
•••
•••

Seattle Jobs

•••
•••
•••
•••